See more : Shanghai Sinotec (Group) Co., Ltd. (603121.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Adagene Inc. (ADAG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adagene Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Melexis NV (MELE.BR) Income Statement Analysis – Financial Results
- Amcor plc (AMC.AX) Income Statement Analysis – Financial Results
- Brookfield Asset Management Ltd. (BAM) Income Statement Analysis – Financial Results
- Geely Automobile Holdings Limited (GELYF) Income Statement Analysis – Financial Results
- NewRiver REIT plc (NRWRF) Income Statement Analysis – Financial Results
Adagene Inc. (ADAG)
About Adagene Inc.
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 18.11M | 9.29M | 10.18M | 480.00K | 480.00K | 1.51M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 18.11M | 9.29M | 10.18M | 480.00K | 480.00K | 1.51M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 36.64M | 81.34M | 68.10M | 16.21M | 16.21M | 16.08M |
| General & Administrative | 8.67M | 11.87M | 14.44M | 3.44M | 3.44M | 2.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.67M | 11.87M | 14.44M | 3.44M | 3.44M | 2.77M |
| Other Expenses | -3.48M | 2.17M | 1.78M | 723.48K | 723.48K | 901.71K |
| Operating Expenses | 41.83M | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Cost & Expenses | 41.83M | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Interest Income | 4.28M | 377.50K | 76.17K | 922.68K | 922.68K | 710.71K |
| Interest Expense | 1.11M | 693.32K | 363.76K | 138.10K | 138.10K | 91.09K |
| Depreciation & Amortization | 1.21M | 1.43M | 1.13M | 858.41K | 816.69K | 909.00K |
| EBITDA | -14.95M | -77.39M | -69.99M | -41.34M | -15.48M | -14.27M |
| EBITDA Ratio | -82.55% | -875.68% | -692.95% | -3,650.73% | -3,480.59% | -980.24% |
| Operating Income | -23.72M | -83.92M | -72.36M | -19.17M | -19.17M | -17.33M |
| Operating Income Ratio | -130.97% | -903.08% | -711.18% | -3,993.68% | -3,993.68% | -1,147.09% |
| Total Other Income/Expenses | 6.46M | 4.41M | 887.77K | 754.38K | 2.74M | 2.07M |
| Income Before Tax | -17.25M | -79.51M | -71.48M | -16.43M | -16.43M | -15.27M |
| Income Before Tax Ratio | -95.27% | -855.65% | -702.45% | -3,423.40% | -3,423.40% | -1,010.22% |
| Income Tax Expense | 1.69M | 459.06K | 1.70M | 3.16K | 861.57K | -547.00K |
| Net Income | -18.95M | -79.97M | -73.18M | -16.44M | -17.29M | -14.72M |
| Net Income Ratio | -104.61% | -860.59% | -719.18% | -3,424.06% | -3,602.89% | -974.03% |
| EPS | -0.44 | -1.85 | -1.83 | -0.47 | -0.39 | -0.43 |
| EPS Diluted | -0.43 | -1.85 | -1.83 | -0.47 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 43.31M | 43.31M | 40.03M | 35.08M | 44.17M | 34.41M |
| Weighted Avg Shares Out (Dil) | 43.79M | 43.31M | 40.03M | 35.08M | 44.17M | 34.41M |
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
Adagene to Present at Investor Conferences in June
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
Source: https://incomestatements.info
Category: Stock Reports